AIManage Using an AI-driven CDS and Chatbot
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: AIManage.
- Who it may be relevant to
- Registry conditions: Diabetes, Obesity, Medication Side Effects. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
AIManage: Using an AI-driven CDS and Chatbot for the Management of Patients on Incretin Mimetic Medications
Overview
The objective of this project is to define and test the GenAI-powered Clinical Decision Support (CDS) tool, AIManage, providing a broad range of incretin mimetic medication management services to optimize dose titrations. The study will take place across primary care and obesity medicine clinics at NYUH. The study is currently conducting formative data collection for tool refinement (Phase 1). Once completed, a cluster randomized controlled trial of the AIManage tool will be undertaken (Phase 2).
Interventions
- Other AIManage
GenAI-powered CDS tool that provides a range of IMM management services, such as personalized guidance for patients on side effects management and clinical advisement to optimize dose titrations.
Primary outcome measures
- Percentage of Patients who Complete Qualitative Measure - Perceived Usefulness [Time frame: Day 1 (60 minutes)]
- Percentage of Patients who Complete Qualitative Measure - Perceived Usability [Time frame: Day 1 (60 minutes)]
- Percentage of Patients who Complete Qualitative Measure - Perceived Use Challenges [Time frame: Day 1 (60 minutes)]
- Percentage of Patients who Complete Qualitative Measure - Perceived Value [Time frame: Day 1 (60 minutes)]
Eligibility criteria
Inclusion criteria
Provider Eligibility Criteria (Phase 1)
- Primary or bariatric care provider (MD/DO, NP) practicing at the participating NYULH clinics,
- Provide care to at least 5 patients prescribed an IMM.
Patient Eligibility Criteria (Phase 1)
- (Phase 1) Currently taking an IMM or have taken an IMM in the past 6 months;
- Fluency in English or Spanish;
- Be willing to send/receive text messages; and
- Be > 18 years of age.
Exclusion criteria
Provider Exclusion Criteria (Phase 1) • Refuse to participate
Patient Exclusion Criteria (Phase 1)
- Refuse or are unable to provide informed consent;
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Non-randomized
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Other
Study locations
United States · 1 center
- NYU Langone Health — New York
Identifiers
NCT: NCT07546357 · 25-00594 · 1R01DK144008